• 6 min read
• Published on 25 July 2025
Listen to article
6:40Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 14 September 2026
Read article
Published on 14 September 2026
Read article
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
In the brutal theatre of biotechnology, nothing is quite as instructive as a good, old-fashioned regulatory rejection. When the European Medicines Agency recently told Sarepta Therapeutics that its gene therapy for Duchenne muscular dystrophy was, in essence, not ready for prime time, it sent a shockwave through the sector. But to me, it wasn't just a story of failure. It was a moment of glorious, clarifying chaos.
Let’s be clear. Duchenne is a devastating genetic disorder, and the market for an effective treatment is, to put it bluntly, enormous. When a frontrunner in such a high-stakes race gets tripped up at the final hurdle, it’s not just a setback for one company. It’s a starting pistol for its rivals. The fog of competition suddenly lifts, and you can see much more clearly who has a real shot at the prize. The path forward, once crowded, now has a few very distinct lanes.
This regulatory shuffle has pushed a few key players into the spotlight. First, you have the 800-pound gorilla, Pfizer. A company of its scale doesn't just dabble. It has the deep pockets and regulatory muscle to navigate the labyrinthine approval process that can confound smaller firms. I think their experience with European regulators could be a significant, if unexciting, advantage.
Then there’s Vertex Pharmaceuticals, a company that has made a name for itself by cracking the code of another rare disease, cystic fibrosis. Their approach is less about brute force and more about deep scientific elegance. They focus on the underlying biology, which might just be the kind of thing that pleases the exacting standards of European regulators.
Finally, we have BioMarin Pharmaceutical, a specialist that lives and breathes rare genetic diseases. This isn't a side project for them, it's their entire reason for being. They understand the nuances of this market better than almost anyone. In a race this specific, being a specialist rather than a generalist could prove to be the winning ticket.
You see, ‘gene therapy’ isn’t some monolithic magic bullet. It’s a field of competing ideas, a bit like a high-stakes science fair where the prize is a multi-billion dollar market. Some companies are trying to deliver new, working genes directly into muscle cells. Others are attempting to edit the faulty genes that are already there. Sarepta’s rejection doesn’t mean gene therapy is a failed concept. It simply suggests that regulators have a preference for certain methods and, crucially, certain standards of proof.
For those of us watching from the investment sidelines, it’s fascinating to see which of these strategies might ultimately prevail. It’s why a collection of these varied contenders, such as the Gene Therapy's Competitive Shift basket, presents such a compelling narrative. You aren't just betting on a single horse, but on the race itself.
Now, before you get carried away and start dreaming of early retirement, let’s pour a little cold water on things. Investing in this space is not for the faint of heart. It’s a rollercoaster designed by mad scientists. Clinical trials can, and frequently do, fail spectacularly. A promising treatment can turn out to be ineffective or unsafe overnight. The volatility is real, and you need a strong stomach for it.
The potential rewards, of course, are what draw people in. A company that develops a breakthrough treatment for a serious disease could see its value multiply. But the key, as always, is understanding that this is a game of probabilities, not certainties. Sarepta’s stumble is a perfect reminder that even the most promising companies can face unexpected hurdles. The race is long, and the outcome is anything but guaranteed.
View the full Basket:Gene Therapy's Competitive Shift
View the full Basket:Gene Therapy's Competitive Shift
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 14 September 2026
Read article
Published on 14 September 2026
Read article
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article